Regeneron Pharmaceuticals, Inc.
$702.27
$6.94(-0.98%)
Regeneron Pharmaceuticals, Inc.
REGN
$702.27
$6.94(-0.98%)
Regeneron Pharmaceuticals, Inc.
REGN
NASDAQ
$702.27
$6.94(-0.98%)
Chart
Upcoming Earnings
Next report date
Jul 30, 2026
Report period
Q3 2026
EPS Estimate
$10.88
Revenue Estimate
$3.82B
Key stats
52-Week Range$702.27
$476.49
$821.11
Market capitalization
$72.35BDividend yield (indicated)
0.51%Price to earnings Ratio (TTM)
16.49Basic EPS (TTM)
$43.12Net income (TTM)
$4.50BRevenue (TTM)
$14.34BAvg. volume
683.59KBeta (1Y)
0.30Employees
15.16KMarket capitalization
$72.35BDividend yield (indicated)
0.51%Price to earnings Ratio (TTM)
16.49Basic EPS (TTM)
$43.12Net income (TTM)
$4.50BRevenue (TTM)
$14.34BAvg. volume
683.59KBeta (1Y)
0.30Employees
15.16KScreener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Regeneron Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
Leonard S. Schleifer
Website
www.regeneron.comHeadquarters
777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707
IPO Date
1991-04-02
Identifiers
ISIN
US75886F1075Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The...
Related Stocks
$369.07
1D:
-0.8%
1Y:
-11.3%
US0367521038Healthcare
Mkt Cap
$80.15B
P/E Ratio TTM
15.7
Revenue TTM
$200.42B
Beta
0.50
Earnings TTM
$5.24B
Dividend Yield TTM
1.84%
$275.66
1D:
-1.3%
1Y:
-17.2%
US1255231003Healthcare
Mkt Cap
$72.68B
P/E Ratio TTM
11.8
Revenue TTM
$274.95B
Beta
0.27
Earnings TTM
$5.96B
Dividend Yield TTM
2.15%
Dividend Overview
Dividend yield (indicated)
0.51%
Dividend per share
$3.58annual
Payout ratio (Earnings)
8.5%
Payout ratio (FCF)
9.0%
Dividend growth streak
0
Dividend CAGR (3Y)
—
Dividend CAGR (5Y)
—
Dividend CAGR (10Y)
—
Dividend yield (indicated)
0.51%
Dividend per share
$3.58annual
Payout ratio (Earnings)
8.5%
Payout ratio (FCF)
9.0%
Dividend growth streak
0
Dividend CAGR (3Y)
—
Dividend CAGR (5Y)
—
Dividend CAGR (10Y)
—
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q3 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q3 '26
Actual
Estimate